Advantages and Disadvantages of Targeting the C-erbB Family of Receptors in Cancer Treatment: A ReviewPanagiotis Papanastasopoulos*
Imperial College, NHS Trust, Charing Cross Hospital, Fulham Palace Rd, London W6 8RF, UK
- Corresponding Author:
- Panagiotis Papanastasopoulos
Imperia l College, NHS Trust
Charing Cross Hospital
Fulham Palace Rd, London W6 8RF, UK
Tel: +44 20 3311 1423
E-mail: [email protected]
Received Date: March 28, 2014; Accepted Date: May 21, 2014; Published Date: May 28, 2014
Citation: Papanastasopoulos P (2014) Advantages and Disadvantages of Targeting the C-erbB Family of Receptors in Cancer Treatment: A Review. Biol Med 6:202. doi:10.4172/0974-8369.1000202
Copyright: © 2014 Papanastasopoulos P. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
C-erbB (EGFR) signaling is well known to promote cancer invasiveness and metastasis. Several pharmacologic approaches have been used aiming to inhibit its activity, ie monoclonal antibodies, antibody-like molecules (peptidomimetics) and receptor tyrosine kinase inhibitors. Several C-erbB signaling ‘inhibitors’, such as Trastuzumab, Cetuximab, gefitinib, erlotinib and lapatinib are now widely used in clinical practice, having revolutionized the management of certain malignancies, such as HER-2 positive breast cancer. In this review, we present an overview of the mechanism of action, pharmacokinetic properties, mechanism of resistance as well as the relative cost of administration for each group of EGFR inhibitors separately.